Cleo Diagnostics Expands Panel to 8 Biomarkers to Strengthen FDA Submission Case
Cleo Diagnostics expands biomarker panel to eight analytes ahead of FDA submission
Cleo Diagnostics (ASX: COV) has completed Cleo Diagnostics Biomarker Panel Optimisation for its Pre-Surgical Ovarian Cancer Test, expanding from five to eight biomarkers. The optimised panel has been specifically designed to improve analytical robustness, inter-assay reproducibility and compatibility with manufacturing processes, positioning the company for its planned FDA 510(k) submission. The expansion represents a critical technical milestone for the pre-revenue diagnostics company as it transitions from research-grade testing to commercial-ready kit production.
The optimised panel has been designed for the high-throughput Ella™ immunoassay platform, which the company selected in February 2026 to support scalable global deployment. A binding manufacturing agreement is expected imminently, with kit production to commence immediately following execution. The company’s manufacturing partner brings established expertise in the development and production of assays for the selected biomarkers, significantly reducing scale-up and manufacturing risk ahead of analytical validation activities.
When big ASX news breaks, our subscribers know first
Why biomarker panel expansion strengthens the test
The expansion to eight biomarkers reduces reliance on any single analyte and mitigates variability often observed in early-stage assay production. This approach strengthens assay reproducibility and reduces technical risk ahead of analytical validation and regulatory submission. Cleo’s patented CXCL10 biomarker remains central to the panel and continues to underpin the company’s proprietary technology.
The Ella™ platform’s microfluidic cartridge architecture enables the simultaneous measurement of multiple biomarkers within a single sample. This allows expansion of the biomarker panel without compromising workflow efficiency, throughput or sample utilisation, which is critical for commercial-scale deployment in diagnostic laboratories.
The three core improvements delivered by the expanded panel include:
- Analytical robustness under real-world clinical conditions
- Inter-assay reproducibility across different production batches
- Manufacturing compatibility for commercial-scale production
What is biomarker panel optimisation and why does it matter for diagnostics?
A biomarker panel is a group of biological markers measured together to improve diagnostic accuracy. Optimisation involves refining the panel composition and testing processes to ensure consistent, reproducible results across different production batches and clinical settings.
For regulatory approval through the FDA 510(k) pathway, a diagnostic test must demonstrate it performs consistently. This is called analytical validation. Expanding from five to eight biomarkers reduces the risk that variability in one analyte compromises the entire test. The additional biomarkers provide redundancy and improve the overall reliability of the assay when manufactured at commercial scale.
Panel optimisation is a standard but critical step in moving from research-grade testing to commercial-ready diagnostics. Completion of this phase signals technical maturity and readiness for the manufacturing and validation activities required to support regulatory submission.
Manufacturing partner aligned as kit production nears
Cleo has worked closely with its preferred manufacturing partner to align on the revised panel. The partner brings established expertise in the development and production of assays for the selected biomarkers, significantly reducing scale-up and manufacturing risk. Manufacturing of analytical validation lots is anticipated to commence immediately following execution of the binding agreement.
The alignment between Cleo and its manufacturing partner accelerates the timeline to FDA submission by ensuring the test kit can be produced consistently at the volumes required for analytical validation. This de-risks the transition from development to commercial production.
Richard Allman, Chief Executive Officer
“Alignment with our manufacturing partner positions us to commence analytical validation imminently – the next key milestone towards our planned FDA submission and entry into the U.S. market.”
Ella™ platform enables scalable global deployment
The Ella™ platform was selected for its high-throughput capability, as announced on 18 February 2026. The microfluidic cartridge architecture allows simultaneous measurement of multiple biomarkers from a single sample, supporting scalable global deployment without compromising performance.
The platform’s compatibility with existing laboratory infrastructure positions Cleo to deploy its test across diagnostic laboratories worldwide once regulatory clearance is obtained. This approach reduces adoption barriers and supports the company’s commercial rollout strategy.
The next major ASX story will hit our subscribers first
Pathway to FDA 510(k) submission and U.S. market entry
Analytical validation is the next key milestone for Cleo Diagnostics Biomarker Panel Optimisation. Successful validation supports the planned FDA 510(k) submission, which would enable entry into the U.S. market for the Pre-Surgical Ovarian Cancer Test. The test aims to distinguish benign from malignant ovarian growths in a standard format readily compatible with existing equipment used by diagnostic laboratories.
The near-term milestones include:
- Binding manufacturing agreement execution (imminent)
- Kit production for analytical validation lots
- Analytical validation activities
- FDA 510(k) submission
The test is backed by over 15 years of research and development at the Hudson Institute of Medical Research, with two clinical studies conducted involving over 500 patients. Cleo holds a worldwide exclusive licence to commercialise the intellectual property underpinning its operations and ovarian cancer tests.
| Attribute | Original Panel | Optimised Panel |
|---|---|---|
| Biomarker count | 5 | 8 |
| Platform | Previous generation | Ella™ |
| Manufacturing readiness | Research-grade | Commercial-scale |
| Regulatory focus | Development | FDA 510(k) submission |
The expanded biomarker panel improves assay robustness and reproducibility under real-world conditions whilst maintaining strong clinical performance. The original biomarker panel demonstrated strong diagnostic performance in distinguishing benign from malignant ovarian disease, establishing a solid foundation for the company’s development programme. The optimisation builds on this foundation by enhancing manufacturability and analytical consistency, which are key requirements for regulatory approval and wider clinical adoption.
U.S. market entry represents the company’s primary near-term commercial opportunity. An accurate and early detection blood test could significantly shift survivability for ovarian cancer, similar to outcomes observed with other cancers. Cleo is advancing the availability of its blood test under a modular execution strategy designed to eventually address all ovarian cancer detection markets with specific tests including surgical triage, recurrence, high-risk screening, and early-stage screening.
Don’t Miss the Next Healthcare Breakthrough
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to start receiving alerts the moment market-moving announcements break.